UHN COVID-19 Biobank , Canada

Registration Status: Completed

Objective: The UHN COVID-19 Biobank is an investigator-initiated biobanking program that collects and archives biological specimens and data obtained from confirmed and/or suspected COVID-19 positive patients and stores them for future research purposes. The UHN COVID-19 was founded in 2020 to test the primary hypothesis of measuring severity markers (i.e. circulating markers of endothelial and immune activation) at clinical presentation are early prognostic indicators of COVID-19. With hopes of expediting and facilitating research amidst the COVID-19 pandemic, the UHN COVID-19 Biobank is a valuable resource that will serve as a library for researchers, facilitating access to high quality biospecimens collected longitudinally throughout the course of the infection. Our biospecimens will be housed indefinitely, as they are essential in understanding key aspects of the disease, including, how to detect infection, how to prevent infection and the development of a COVID-19 vaccine and/or potential treatments. Our highly trained personnel at UHN Biospecimen Services can provide expertise and services in: recruitment, consenting, procurement, processing, storage and shipment of biofluids.

Registered Biobank Name	UHN COVID-19 Biobank
Biobank Leader	Heidi Wagner
Country	Canada
Email for biobank inquiries	Heidi.Wagner@uhn.ca
Principal Investigator	Dr. Neil Fleshner (Principal Investigator) and Heidi Wagner (Head of Operations)
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).